Clarity Pharmaceuticals Ltd (ASX:CU6)
Australia · Delayed Price · Currency is AUD 2.100
+0.010 (0.48%)
Sep 17, 2026, 4:10 PM AEST
Clarity Pharmaceuticals Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Other Revenue | 10.53 | 9.46 | 11.51 | 9.8 | 6.46 |
| 10.53 | 9.46 | 11.51 | 9.8 | 6.46 | |
Revenue Growth | 11.24% | -17.76% | 17.41% | 51.74% | 102.07% |
Gross Profit | 10.53 | 9.46 | 11.51 | 9.8 | 6.46 |
Selling, General & Admin | 27.83 | 11.68 | 9.94 | 4.71 | 4.61 |
Research & Development | 91.08 | 66.88 | 45.78 | 31.46 | 18.9 |
Operating Expenses | 118.91 | 78.56 | 55.72 | 36.16 | 23.51 |
Operating Income | -108.38 | -69.09 | -44.21 | -26.36 | -17.05 |
Interest & Investment Income | 8 | 4.76 | 2.77 | 1.86 | 0.1 |
Currency Exchange Gain (Loss) | -5.91 | 0.45 | -0.59 | - | - |
EBT Excluding Unusual Items | -106.28 | -63.88 | -42.03 | -24.5 | -16.95 |
Other Unusual Items | - | - | - | - | -6.78 |
Pretax Income | -106.28 | -63.88 | -42.03 | -24.5 | -23.74 |
Income Tax Expense | 0.86 | 0.42 | 0.3 | 0.1 | 0.02 |
Earnings From Continuing Operations | -107.14 | -64.3 | -42.32 | -24.6 | -23.75 |
Earnings From Discontinued Operations | -0.1 | - | - | - | - |
Net Income | -107.24 | -64.3 | -42.32 | -24.6 | -23.75 |
Net Income to Common | -107.24 | -64.3 | -42.32 | -24.6 | -23.75 |
Net Income Growth | - | - | - | - | - |
Shares Outstanding (Basic) | 368 | 319 | 273 | 260 | 248 |
Shares Outstanding (Diluted) | 368 | 319 | 273 | 260 | 248 |
Shares Change | 15.30% | 16.86% | 5.22% | 4.81% | 40.37% |
EPS (Basic) | -0.29 | -0.20 | -0.15 | -0.09 | -0.10 |
EPS (Diluted) | -0.29 | -0.20 | -0.15 | -0.10 | -0.10 |
EPS Growth | - | - | - | - | - |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Free Cash Flow | -92.85 | -54.95 | -43.74 | -27.55 | -13.53 |
Free Cash Flow Per Share | -0.25 | -0.17 | -0.16 | -0.11 | -0.06 |
Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
Operating Margin | -1029.61% | -730.16% | -384.24% | -269.00% | -263.94% |
Profit Margin | -1018.80% | -679.45% | -367.82% | -251.03% | -367.78% |
Free Cash Flow Margin | -882.10% | -580.71% | -380.14% | -281.07% | -209.43% |
EBITDA | -108.1 | -68.91 | -44.06 | -26.26 | -17 |
EBITDA Margin | - | - | - | -267.97% | -263.22% |
D&A For EBITDA | 0.28 | 0.19 | 0.15 | 0.1 | 0.05 |
EBIT | -108.38 | -69.09 | -44.21 | -26.36 | -17.05 |
EBIT Margin | - | - | - | -269.00% | -263.94% |
Revenue as Reported | 18.53 | 14.23 | 14.28 | 11.66 | 6.55 |